Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug in lung cancer, after beating its parent in a phase 3 trial.

Lorbrena is already approved in the U.S. for treating adults with advanced non-small cell lung cancer who have a mutation in a gene called ALK. Pfizer will present the results on Friday at the ...

Pfizer’s drug Lorbrena (lorlatinib) can be used to treat certain types of advanced lung cancer. The US Food and Drug Administration (FDA) approved the treatment for patients with a specific gene ...

Pfizer PFE will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus ...

Articles and videos about Fox News on Fox News.

Here are three dividend stocks that retirees can buy with confidence as they offer recurring, dependable payouts and a degree ...